New Tx for Relapsing MS Moves Closer to Approval as FDA Accepts BLA for Review

Biogen and AbbVie announced that the Food and Drug Administration (FDA) has accepted their Biologics License Application (BLA) for review for Zinbryta (daclizumab high-yield process) in relapsing forms of multiple sclerosis (MS).

The BLA included results from two pivotal trials, DECIDE and SELECT, in which Zinbryta 150mg was administered subcutaneously every four weeks in people with relapsing-remitting MS.